About the Company
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CBAY News
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer ...
3 Dividend Stocks to Buy Hand Over Fist in March
Get paid to own a stock whether it moves higher or lower. What a concept! And it's one that any investor who buys dividend ...
Maintaining Hold on CymaBay Amid Gilead Acquisition Deal Closure
Analyst Ed Arce of H.C. Wainwright maintained a Hold rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of ...
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...
Perrigo has no exposure to infant formula litigation, CG says
Perrigo (PRGO) has no exposure to lawsuits over the safety of premature infant formula that have been filed against rivals ...
Buy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial Position
Akebia Therapeutics (AKBA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...
Cymabay Therapeutics Inc (NASDAQ: CBAY) Up 271.63% This Year: What Is Going To Happen Next
Cymabay Therapeutics Inc (NASDAQ:CBAY) price is hovering higher on Wednesday, March 06, jumping 0.17% above its previous close. A look at today’s price movement shows that the recent level at last ...
GILD Jan 2025 110.000 put
March 11, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s ...
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust ...
iRhythm Technologies, Inc.
iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services ...
Before Buying Cyclo Therapeutics Inc (NASDAQ: CYTH) Stock, Read This First
Cyclo Therapeutics Inc (NASDAQ:CYTH) shares, rose in value, without any change to the previous day’s close as strong demand from buyers drove the stock to $1.62. Actively observing the price movement ...
Loading the latest forecasts...